Key Insights

Highlights

Success Rate

87% trial completion (above average)

Published Results

34 trials with published results (27%)

Research Maturity

74 completed trials (59% of total)

Clinical Risk Assessment

Based on trial outcomes

Low Risk

Score: 17/100

Termination Rate

8.7%

11 terminated out of 126 trials

Success Rate

87.1%

+0.6% vs benchmark

Late-Stage Pipeline

31%

39 trials in Phase 3/4

Results Transparency

46%

34 of 74 completed with results

Key Signals

34 with results87% success11 terminated

Data Visualizations

Phase Distribution

94Total
Not Applicable (29)
Early P 1 (2)
P 1 (8)
P 2 (16)
P 3 (29)
P 4 (10)

Trial Status

Completed74
Recruiting12
Withdrawn11
Terminated11
Unknown10
Active Not Recruiting5

Trial Success Rate

87.1%

Benchmark: 86.5%

Based on 74 completed trials

Clinical Trials (126)

Showing 20 of 20 trials
NCT00169637Phase 3CompletedPrimary

Evaluation of the Efficacy and Safety of Recombinant Human Growth Hormone (rhGH) in the Treatment of Children With Short Bowel Syndrome

NCT04775706Phase 2RecruitingPrimary

Phase 2 Study to Assess the Safety, PK, and PD of Sonefpeglutide (HM15912) in SBS-IF Subjects

NCT07197944Phase 3RecruitingPrimary

Efficacy And Safety Evaluation of Glepaglutide in Treatment of SBS

NCT05023382Active Not RecruitingPrimary

A Study of Teduglutide in Japanese People With Short Bowel Syndrome

NCT06512584Phase 3RecruitingPrimary

Efficacy and Safety of PJ009 in Patients With Short Bowel Syndrome Requiring Parenteral Nutrition

NCT06771505RecruitingPrimary

SBS DISK- Creation of a Quality of Life Tool for Short Bowel Patients Compared With a Validated Quality of Life Questionnaire (SBS QoL)

NCT06326645Early Phase 1RecruitingPrimary

Open-Label Pilot Study With Crofelemer in Patients With Short Bowel Syndrome

NCT04881825Phase 3Active Not RecruitingPrimary

Evaluation of Long Term Safety and Efficacy of Glepaglutide in Treatment of SBS - Extension Trial

NCT03905707Phase 3Active Not RecruitingPrimary

Evaluation of Long Term Safety and Efficacy of Glepaglutide in Treatment of SBS

NCT06938542Not ApplicableEnrolling By Invitation

Palliative Care Needs of Children With Rare Diseases and Their Families

NCT05635747Enrolling By InvitationPrimary

A 90 Day Observational Study as an Extension to the Phase 3,Open Labeled Exploratory Study of RELiZORB

NCT03530852Not ApplicableRecruitingPrimary

A 90 Day, Phase 3,Open Labeled Exploratory Study of RELiZORB

NCT07235670Not ApplicableCompletedPrimary

Gastrointestinal Hormone Secretion, Intestinal Permeability and Short Bowel Syndrome

NCT01990040Active Not RecruitingPrimary

Registry for Participants With Short Bowel Syndrome

NCT05535361Not ApplicableRecruitingPrimary

A Feasibility Study to Evaluate Safety and Probable Benefit of the Eclipse XL1 System for Distraction Enterogenesis in Adult and Pediatric Patients With Short Bowel Syndrome

NCT07206004Not Yet RecruitingPrimary

Effect of Parenteral Support on FibroScan in Short Bowel Syndrome

NCT04743960Not ApplicableCompleted

Assessing Metabolic and Sleep Consequences of Overnight Home Parenteral Nutrition

NCT07186608Not ApplicableCompletedPrimary

Specific Dietary Fibers May Enhance Colonic Adaptation in Short Bowel Syndrome Through Microbial and Metabolic Mechanisms That Drive Functional Compensation.

NCT03562130Phase 4CompletedPrimary

Characterization of the Long-term Safety, Efficacy, and Pharmacodynamics Revestive® in the Management of Short Bowel Syndrome Pediatric Patients

NCT03690206Phase 3CompletedPrimary

Efficacy And Safety Evaluation of Glepaglutide in Treatment of Short Bowel Syndrome (SBS)

Scroll to load more

Research Network

Activity Timeline